MI-mAbs, the French demonstrator of immunotherapy antibodies launched in the framework of «Investissements d’Avenir» inaugurated its building on 5 July in the heart of MI-Biopark. Thanks to this new tool that will soon be expanded by a pilot-scale antibody bioproduction facility, MI-mAbs intends to accelerate the R&D programs of its academic and industrial clients and to ensure its financial autonomy by end 2019.The videos of the inauguration of the MI-mAbs building are available on the vimeo channel of MI-mAbs.
«MI-mAbs is emblematic of Aix-Marseille University’s strategy in terms of knowledge, research and innovation as it both accelerates the transfer of innovation, to support the economic development of our region and offers a real-life testing ground to our students,»says Professor Yvon BERLAND, President of Aix-Marseille University «It also testifies to our excellence in the field of fundamental and applied immunology. From the creation of the Immunology Center of Marseille-Luminy to Marseille Immunopole (MI), by way of a successful spin-off such as Innate Pharma, Marseille has progressively imposed itself as the leader in a discipline that is changing the fate of thousands of patients.»
«In 2010, immunotherapy started to keep its promise and Marseille had already contributed to this progress but it unquestionably lacked a tool to acclerate and de-risk the R&D of these new antibodies, »recalls Dr Hervé BRAILLY, Chairman of the Supervisory Board and co-founder, Innate Pharma«With Eric VIVIER, François ROMAGNÉ, Jean-Paul BORG and Bernard MALISSEN our idea was to entrust the crucial phase of target validation and selection of the candidate antibody to an expert center that was positioned at the interface between research and industry. This is what MI-mAbs does today, with a program of antibodies from the collaboration between Innate Pharma and Sanofi and what it will now be able to scale up in this new building».
«Through its commitment to MI-mAbs, Sanofi confirms its determination to bring innovative biotherapies to patients with cancer and inflammatory diseases for which unmet medical needs are still significant » says Dr Marc BONNEFOI, Vice-President, R&D Sanofi France«To speed up innovation and to meet patients’ needs in these fields, we have chosen one again to associate our expertise with partners of excellence, in this case in immunology».
«As its name implies, MI-mAbs (MI monoclonal antibodies) is at the heart of MI’s strategy. The demonstrator is positioned up the bispecific antibody R&D value chain. For a given target, we generate the antibody candidates, we evaluate their development potential by studying their efficacy in vitro and in vivo. Our clinical colleagues at the IPC and scientists at the Center for Immunophenomics (CIPHE) support us in this work by providing us with biological samples from patients and animal models. Once selected, these antibody candidates will be able to integrate the clinical trial programs implemented at the IPC and the AP-HM. Together with the other MI platforms, MI-mAbs contributes to accelerating every stage of R&D, providing academic scientists with the expertise in development that they lack and offering industrial access to original models and an R&D relay that is close to the key players in the world of research,»adds Prof. François ROMAGNÉ, Director, MI-mAbs« Initially coordinated by Professor Eric VIVIER, MI-mAbs has already conducted 15 R&D projects and engaged two integrated development programs for different industrial and academic partners. Thanks to support from the State, and local authorities, we now benefit from a high-tech building that will allow us to conduct up to four integrated programs per year».